Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Apogee Therapeutics, Inc.NASDAQ: APGE
Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026
Income tax expense grows, but more slowly than its trailing trend
Q2 FY2026 income tax expense of $78K rose 8.3% year over year, behind the +61.8% change in trailing-twelve-month income tax expense. Sequentially, it fell 1.3% from the prior quarter.
Context
- Income tax expense increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +8.3% toward the trailing-twelve-month pace of +61.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 278K USD
- Year-over-year change
- +1444.4%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 278K | +1444.4% |
| FY2024 | 2024-12-31 | 18K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Income Tax Expense vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +61.8% is the 3rd highest of 7, against a peer median of +13.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.42M USD | +88.3% | +183.2% | 2.4% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥6.75M CNY | -35.2% | — | 1.2% |
| LTM Mar 2026 | $3.82M USD | +55.8% | -11.1% | 0.6% | |
| LTM Mar 2026 | $1.27M USD | -66.2% | — | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $317K USD | -29.4% | — | — |
| LTM Jun 2026 | $280K USD | +61.8% | — | — | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| LTM Sep 2026 | -$775K USD | +77.0% | +105.0% | — | |
| LTM Jun 2026 | -$2.51M USD | — | — | 0.6% | |
| Peer median (excluding APGE) | — | +13.2% | +105.0% | 0.6% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.42M |
| Gross Profit | 0 | 0 | 0 | (1.42M) |
| Gross Margin | — | — | — | — |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| Operating Expenses | 30.73M | 93M | 216.87M | 284.18M |
| Depreciation & Amortization | 0 | 9.02M | 189K | 1.42M |
| EBITDA | (39.79M) | (74.97M) | (181.94M) | (254.15M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (30.73M) | (93M) | (216.87M) | (285.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income / Expenses | (9.06M) | 9.02M | 34.74M | 30.03M |
| Income Before Tax | (39.79M) | (83.99M) | (182.13M) | (255.57M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 18K | 278K |
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.79) | (1.66) | (3.30) | (4.22) |
| EPS (Diluted) | (0.79) | (1.66) | (3.30) | (4.22) |
| Weighted Avg Shares | 50.67M | 50.66M | 55.19M | 60.69M |
| Weighted Avg Shares (Diluted) | 50.67M | 50.66M | 55.19M | 60.69M |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.